Your session is about to expire
← Back to Search
Ofatumumab + Siponimod vs Fingolimod for Pediatric Multiple Sclerosis (NEOS Trial)
NEOS Trial Summary
This trial showed that ofatumumab and siponimod are more effective and safer than fingolimod in treating multiple sclerosis in children.
NEOS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowNEOS Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.NEOS Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had at least one MS flare-up in the last year or two in the last two years, or new brain lesions.My disability level allows me to walk without aid or rest for at least 200 meters.I have severe kidney problems.My MS is getting worse.I have a chronic immune system disease other than MS.I am between 10 and 17 years old.I do not have severe heart disease or alarming ECG results.I have been diagnosed with multiple sclerosis.
- Group 1: siponimod - 0.5 mg, 1 mg or 2 mg/ placebo
- Group 2: fingolimod - 0.5 mg or 0.25 mg/ placebo
- Group 3: ofatumumab - 20 mg injection/ placebo
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any other drugs that have a similar chemical structure to Siponimod?
"Siponimod was first studied a decade ago at National Institutes of Health Clinical Center. Since the initial study, there have been a total of 125 completed clinical trials. There are presently 32 active studies happening across the world, with a large concentration in Atlanta, Georgia."
What is the age range of patients that are able to enroll in this research project?
"According to the eligibility requirements, participants must be aged between 10 and 17."
What are the primary Siponimod indications?
"Siponimod is used to treat leukemia and other disorders like multiple sclerosis. When patients are unresponsive to fludarabine and alemtuzumab or ineligible for fludarabine-based therapy, siponimod can be an effective treatment option."
Are there numerous sites running this experiment in America?
"To make participating in this clinical trial as convenient as possible for enrollees, it is being run out of 8 different centres located in cities across America, such as Atlanta, Salt Lake City and San Diego."
What is the known risk profile for Siponimod?
"Siponimod has been evaluated for safety in Phase 3 trials, meaning that there is some evidence to support its efficacy as well as multiple rounds of data to support its safety. Our team at Power has estimated the safety of Siponimod to be a 3 on a scale from 1 to 3."
Can members of the public still sign up for this clinical trial?
"Yes, the latest information from clinicaltrials.gov shows that this study is still open for recruitment. The trial was created on 10/5/2021, and the most recent update was on 10/4/2022. A total of 180 participants are needed, and there are currently 8 sites enrolling patients."
If I qualify, can I take part in this experiment?
"This particular medical trial is open to 180 patients that are aged 10-17 and have a diagnosis of multiple sclerosis. Aside from meeting this age and disease criteria, potential participants must also have an Expanded Disability Status Scale (EDSS) score of 0-5.5 and have had either one relapse in the past year or two relapses in the past two years. Lastly, there must be evidence of one or more new T2 lesions within the past 12 months."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger